Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) EPS (Basic) (2018 - 2025)

Serina Therapeutics' EPS (Basic) history spans 8 years, with the latest figure at -$0.45 for Q3 2025.

  • For Q3 2025, EPS (Basic) fell 190.0% year-over-year to -$0.45; the TTM value through Sep 2025 reached -$1.87, down 128.05%, while the annual FY2024 figure was -$1.51, 163.98% down from the prior year.
  • EPS (Basic) for Q3 2025 was -$0.45 at Serina Therapeutics, up from -$0.66 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $3.64 in Q2 2024 and bottomed at -$9.5 in Q4 2022.
  • The 5-year median for EPS (Basic) is -$0.07 (2021), against an average of -$0.63.
  • The largest annual shift saw EPS (Basic) tumbled 15733.33% in 2022 before it soared 5300.0% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.06 in 2021, then crashed by 15733.33% to -$9.5 in 2022, then surged by 104.42% to $0.42 in 2023, then tumbled by 164.29% to -$0.27 in 2024, then crashed by 66.67% to -$0.45 in 2025.
  • Per Business Quant, the three most recent readings for SER's EPS (Basic) are -$0.45 (Q3 2025), -$0.66 (Q2 2025), and -$0.49 (Q1 2025).